Spots Global Cancer Trial Database for mpnst
Every month we try and update this database with for mpnst cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas | NCT05253131 | MPNST NF1 Sarcoma | Selumetinib | 18 Years - 99 Years | University of Alabama at Birmingham | |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | NCT05985161 | Wilms Tumor Rhabdoid Tumor Malignant Perip... MPNST Nephroblastoma XPO1 Gene Mutat... Solid Tumor | Selinexor | 12 Months - | Memorial Sloan Kettering Cancer Center | |
| A Study of Pembrolizumab in Patients With Malignant Peripheral Nerve Sheath Tumor (MPNST), Not Eligible for Curative Surgery | NCT02691026 | Malignant Perip... | Pembrolizumab | 18 Years - | Oslo University Hospital | |
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | NCT06222203 | Neurofibromatos... Nerve Sheath Ne... | 3 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | NCT05985161 | Wilms Tumor Rhabdoid Tumor Malignant Perip... MPNST Nephroblastoma XPO1 Gene Mutat... Solid Tumor | Selinexor | 12 Months - | Memorial Sloan Kettering Cancer Center | |
| Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs | NCT01218152 | Neurofibromatos... | - | KU Leuven | ||
| Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST) | NCT06222203 | Neurofibromatos... Nerve Sheath Ne... | 3 Years - 120 Years | National Institutes of Health Clinical Center (CC) | ||
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients | NCT01218139 | Neurofibromatos... | - | KU Leuven | ||
| Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients | NCT01218139 | Neurofibromatos... | - | KU Leuven | ||
| SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors) | NCT02008877 | Malignant Perip... Sarcoma | ganetespib Sirolimus | 16 Years - | Sarcoma Alliance for Research through Collaboration | |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | NCT05275478 | Locally Advance... | TNG908 | 18 Years - | Tango Therapeutics, Inc. | |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | NCT05732831 | Locally Advance... | TNG462 | 18 Years - | Tango Therapeutics, Inc. | |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | NCT01661283 | Malignant Perip... MPNST Sarcoma | everolimus bevacizumab | 18 Years - | Sarcoma Alliance for Research through Collaboration | |
| SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors | NCT01661283 | Malignant Perip... MPNST Sarcoma | everolimus bevacizumab | 18 Years - | Sarcoma Alliance for Research through Collaboration |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
